Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rajeev Nagpal

Pediatric Gastroenterology Oak Lawn, IL Medical Doctor

NPI 1396731329 CMS profile 1287397

4440 W 95Th St, Oak Lawn, IL 60453

Open in the dashboard

General payments

$6,301

326 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rajeev Nagpal of Oak Lawn, IL is reported in the CMS Open Payments database as having received $6,301 across 326 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Pediatric Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,135 51
2024 General $1,741 97
2023 General $1,612 77
2022 General $602 34
2021 General $571 37
2020 General $281 14
2019 General $360 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rajeev Nagpal
  • Pediatric Gastroenterology median
  • Middle half of Pediatric Gastroenterology
  • National median

In program year 2025, general payments to Rajeev Nagpal were reported at $1,135. Among 1,132 Pediatric Gastroenterology profiles paid that year, the median was $194 and the middle half received between $81 and $540.

Show as a table
Year Rajeev Nagpal Pediatric Gastroenterology median Middle half National median
2019 $360 $131 $41–$311 $163
2020 $281 $79 $23–$223 $114
2021 $571 $104 $32–$321 $132
2022 $602 $125 $37–$331 $149
2023 $1,612 $169 $55–$440 $160
2024 $1,741 $196 $73–$563 $164
2025 $1,135 $194 $81–$540 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,654 92 payments
  2. Regeneron Healthcare Solutions, Inc. $861 51 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $807 49 payments
  4. QOL Medical, LLC $669 35 payments
  5. Genzyme Corporation $566 24 payments
  6. Mirum Pharmaceuticals, Inc. $548 23 payments
  7. Sandoz Inc. $177 9 payments
  8. Nestle HealthCare Nutrition Inc. $156 8 payments
  9. Ipsen Biopharmaceuticals, Inc $152 6 payments
  10. Janssen Biotech, Inc. $103 5 payments
  11. Other $608 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,284 325 payments
  2. Education $17 1 payment
Products named General payments · program years 2019–2025
  1. HUMIRA $689 42 payments
  2. ENTYVIO $556 31 payments
  3. Livmarli $548 23 payments
  4. DUPIXENT Inflammation And Immunology $533 36 payments
  5. DUPIXENT Immunology $433 22 payments
  6. Sucraid $409 22 payments
  7. RINVOQ $398 19 payments
  8. CREON $358 24 payments
  9. DUPIXENT Immunology And Inflammation $328 15 payments
  10. SKYRIZI $321 13 payments
  11. Other $1,810 92 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

326 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Gastroenterology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record